NASDAQ · AVR
Healthcare · Medical - Devices
$9.25
Down-$0.27 (-2.92%)
Updated Aug 22, 2026, 1:02 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AVR closed at $9.25 after 20 trading sessions, up 13.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $9.68 | $9.89 | $9.085 | $9.25 | 1.17M |
| Aug 19, 2026 | $9.72 | $10.10 | $9.385 | $9.83 | 1.26M |
| Aug 18, 2026 | $9.36 | $9.70 | $9.35 | $9.58 | 720.9K |
| Aug 17, 2026 | $9.27 | $9.60 | $9.21 | $9.42 | 488.19K |
| Aug 14, 2026 | $8.84 | $9.42 | $8.725 | $9.40 | 683.46K |
| Aug 13, 2026 | $8.85 | $9.13 | $8.84 | $8.93 | 447K |
| Aug 12, 2026 | $9.03 | $9.0925 | $8.59 | $8.87 | 832.92K |
| Aug 11, 2026 | $9.02 | $9.46 | $9.00 | $9.17 | 1.11M |
| Aug 10, 2026 | $8.80 | $9.24 | $8.79 | $8.96 | 1.07M |
| Aug 7, 2026 | $8.51 | $8.92 | $8.465 | $8.91 | 502.59K |
| Aug 6, 2026 | $7.96 | $8.56 | $7.95 | $8.36 | 987.07K |
| Aug 5, 2026 | $8.26 | $8.3662 | $7.985 | $8.05 | 584.54K |
| Aug 4, 2026 | $8.325 | $8.43 | $8.17 | $8.28 | 1.27M |
| Aug 3, 2026 | $7.86 | $8.48 | $7.86 | $8.28 | 1.43M |
| Jul 31, 2026 | $8.27 | $8.39 | $7.725 | $7.84 | 1.03M |
| Jul 30, 2026 | $8.03 | $8.33 | $8.00 | $8.24 | 1.44M |
| Jul 29, 2026 | $7.95 | $8.22 | $7.88 | $7.90 | 876.09K |
| Jul 28, 2026 | $8.15 | $8.43 | $7.75 | $8.17 | 1.5M |
| Jul 27, 2026 | $8.24 | $8.47 | $8.08 | $8.17 | 838.23K |
| Jul 24, 2026 | $8.32 | $8.39 | $8.05 | $8.13 | 503.46K |
The latest Smart Investors Daily articles mentioning AVR.
AVR research
Company profile and research snapshot.
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Barclays | Overweight | — |
| Mar 27, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 11, 2026 | Wells Fargo | Overweight | — |
| Jan 8, 2025 | Lake Street | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and maintains $15 price target.
Benzinga · Aug 12, 2026
Anteris Technologies Glb (NASDAQ:AVR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.21) by 42.86 percent. This is a 48.28 percent increase over losses of $(0.58) per
Yahoo · Aug 11, 2026
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) made progress on its pivotal PARADIGM Trial during the June quarter, enrolling and treating its first US patients after securing Medicare reimbursement eligibility for qualifying procedures. The company also expanded recruitment across...
Yahoo · Aug 11, 2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Secured U.S. Medicare reimbursement eligibility for the global pivotal P
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVR.
